Fig. 3: Significant changes in the metabolism between HT and healthy control groups.

a PLS-DA between the control and HT groups (negative mode). b Validation of the PLS-DA model (negative mode). c Volcano map of the metabolites screened between the HT and control groups and was built based on log2(fold change) and -log10(p-value) (negative mode). d The top 16 KEGG pathways related to differentially expressed metabolites between the HT and control groups. e Heatmap of correlations between the five clinical indicators of HT and the significantly changed metabolites in patients with HT. The color bar with numbers indicates the correlation coefficients. f The concentrations of SCFAs in the serum of HT and control groups were determined by GC-MS.